RxDoctor Payments Data

Kelly Anne Spratt, DO

Cardiovascular Disease · Philadelphia, PANPI 1477580363

Payments from drug & device makers

$233in general payments, 2019–2025

Across 10 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$77
  • Johnson & Johnson$45
  • Cardiac Dimensions, Inc.$30
  • Cvrx, Inc.$28
  • Impulse Dynamics (USA) Inc.$25
  • W. L. Gore & Associates, Inc.$14
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$233100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$233 in reported general payments places this provider in the 15th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$198,677
Medicare patients
1,122
Services billed
3,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban450$514,704
XareltoRivaroxaban168$221,792
Repatha SureclickEvolocumab222$183,685
EntrestoSacubitril/Valsartan84$103,626
Praluent PenAlirocumab85$61,554
JardianceEmpagliflozin36$35,260
WegovySemaglutide15$19,628
Metoprolol Succinate926$16,455
Ezetimibe396$13,845
Rosuvastatin Calcium533$9,155
Losartan Potassium577$6,511
Atorvastatin Calcium457$5,789
Pantoprazole Sodium45$5,437
Midodrine Hcl71$4,494
Valsartan90$3,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$45$221,792168 claims
Novo NordiskWegovy$14$19,62815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →